Related Experiment Video
Updated: Jun 20, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in patients with heart failure
R Sacha Bhatia1, Maral Ouzounian, Jack V Tu
1Institute for Clinical Evaluative Sciences, Toronto, Ontario, M4N 3M5 Canada.
Cardiovascular & Hematological Agents in Medicinal Chemistry
|August 20, 2009
Summary
Anticoagulating heart failure (HF) patients is challenging due to limited data. More research is needed to clarify risks and benefits of anticoagulation for preventing thromboembolic events in HF.
Area of Science:
- Cardiology
- Hematology
- Clinical Research
Background:
- Thromboembolic events (stroke, DVT, PE) are major causes of mortality and morbidity in heart failure (HF) patients.
- Pathophysiology involves stasis, endothelial dysfunction, and hypercoagulability, exacerbated by HF-related inflammation and neuroendocrine activation.
- Existing data on epidemiology and risk factors for these events in HF is limited and often confounded by atrial fibrillation.
Purpose of the Study:
- To review health outcomes research on etiological factors, prevalence, and impact of thromboembolic events in heart failure.
- To synthesize data on therapeutic agents and review recent clinical trials concerning anticoagulation in HF.
- To identify gaps in knowledge regarding systemic anticoagulation for HF patients.
Main Methods:
- Review of existing health outcomes research.
- Synthesis of data on various classes of therapeutic agents.
- Analysis of findings from recent clinical trials (WATCH, WASH, WARCEF).
Main Results:
- Conflicting analyses exist regarding the risks and benefits of prophylactic anticoagulation in HF.
- Data on specific etiological factors, prevalence, and impact of thromboembolic events in HF is poorly defined.
- Recent trials have not provided compelling evidence to guide anticoagulation decisions in HF.
Conclusions:
- The decision to anticoagulate heart failure patients remains complex due to insufficient clinical trial data.
- Further research is essential to establish clear guidelines for anticoagulation strategies in HF.
- Unanswered questions persist regarding the efficacy and safety of systemic anticoagulation in this population.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...